Solution for Type 1A Endoleaks After Abdominal Endoprosthesis

Proximal type 1 endoleaks after endovascular abdominal aortic aneurysmal repair are challenging to solve, with no existing consensus on the proper solution.

This work compared the most radical solution to the problem vs. a more conservative—though still challenging—option.

The first one was the surgical explantation of the endoprosthesis with aortic reconstruction, while the more “conservative” one was a customized fenestrated endoprosthesis.

This retrospective analysis included patients who, between 2009 and 2018, underwent one of the aforementioned two options to resolve a type 1A endoleak. Operators made the decision based on anatomy (fenestrated prosthesis eligibility), sac growth rate, and emergency or symptomatic presentation.

There were only 59 patients found who met these criteria in the almost 10 years included, but this is very useful information because of the scarcity of data and the risks of both strategies.


Read also: Data that Can Change TAVR and SAVR Strategy.


Endoprosthesis explantation and aortic reconstruction were performed in 26 patients, while implantation of a customized fenestrated endoprosthesis was conducted in 33 cases.

Both groups were similar in age and comorbidities at the time of procedure. Mean time between original endoprosthesis and new procedure was 60.4 months (34-85 months).

The maximum aneurysm diameter was greater in the surgical explantation and reconstruction group (86 mm vs. 70 mm, p = 0.008)

Secondary interventions at 30 days (11.5% vs. 9.1%) and mortality (3.8% vs. 3.3%) were similar between groups.


Read also: Revascularization Is Needed Before TAVR.


The rates of major adverse events, as defined by the Society for Vascular Surgery guidelines, were lower in the groups treated with fenestrated endoprosthesis (2.4% vs. 13.6%; p = 0.016).

After a year of follow-up, survival was similar in both groups (84% vs. 86.6%).

Conclusion

Both endoprosthesis explantation with aorta reconstruction and fenestrated endoprosthesis implantation are satisfactory solutions in high-volume and experienced centers for the treatment of type 1A leaks.

Fenestrated prosthesis has a lower initial morbidity, but its elaboration takes time, which many patients do not have. In these cases, surgery is an excellent choice.

Original Title: After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair.

Reference: Benoit Doumenc et al. Eur J Vasc Endovasc Surg. 2021. Online ahead of print doi: 10.1016/j.ejvs.2020.10.033.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

C-TRACT: Endovascular therapy in post-thrombotic syndrome due to iliac obstruction

Post-thrombotic syndrome (PTS) is one of the most limiting sequelae following proximal deep vein thrombosis (DVT). It clinically manifests as chronic pain, edema, skin...

Coil embolization of segmental arteries as a spinal cord protection strategy prior to complex endovascular repair of thoracoabdominal aorta

Spinal cord ischemia remains one of the most devastating complications in the repair of thoracoabdominal aneurysms, with incidences of up to 20–30% in extensive...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...